Science Explorer Back to mapMap
Institution · Shikoku Cancer Center

Most cited papers from Shikoku Cancer Center

What are the most cited papers from Shikoku Cancer Center?

The most cited paper from Shikoku Cancer Center is "Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer" (Jean‐Charles Soria et al., 2017), with 5,475 citations. Next come "Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC" (3,816) and "Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine" (2,547).

Showing 50 of 60 papers. Every paper with more than 201 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria et al. · New England Journal of Medicine Open access 18 Nov 2017 5,475
2 Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine Open access 4 Jun 2018 3,816
3 Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine Open access 31 Oct 2007 2,547
4 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi et al. · New England Journal of Medicine Open access 11 Dec 2019 2,026
5 Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Norikazu Masuda et al. · New England Journal of Medicine Open access 31 May 2017 1,947
6 A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) Nobutoshi Ando, Hoichi Kato, Hiroyasu Igaki et al. · Annals of Surgical Oncology Open access 30 Aug 2011 1,459
7 D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer Mitsuru Sasako, Takeshi Sano, Seiichiro Yamamoto et al. · New England Journal of Medicine Open access 30 Jul 2008 1,029
8 Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial Martin Reck et al. · The Lancet Respiratory Medicine 26 Mar 2019 954
9 Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Toyoaki Hida et al. · The Lancet 11 May 2017 927
10 CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho et al. · Journal of Clinical Oncology Open access 28 Aug 2018 804
11 Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy—Japan Clinical Oncology Group Study 9501 Takeshi Sano, Mitsuru Sasako, Seiichiro Yamamoto et al. · Journal of Clinical Oncology 17 Jun 2004 679
12 Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial Robert M. Jotte, Federico Cappuzzo, Ihor O. Vynnychenko et al. · Journal of Thoracic Oncology Open access 14 Apr 2020 618
13 Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Narikazu Boku, Seiichiro Yamamoto, Haruhiko Fukuda et al. · The Lancet Oncology 9 Oct 2009 594
14 CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study Takashi Seto, Katsuyuki Kiura, Makoto Nishio et al. · The Lancet Oncology 29 Apr 2013 579
15 Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology 4 Nov 2013 570
16 IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology Open access 24 Jul 2021 546
17 Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial Norio Kohno, Kenjiro Aogi, Hironobu Minami et al. · Journal of Clinical Oncology Mar 2005 546
18 Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer Yasuhide Yamada et al. · Annals of Oncology Open access 15 Oct 2014 546
19 Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial Mitsue Saito, Kenjiro Aogi, Ikuo Sekine et al. · The Lancet Oncology 9 Jan 2009 437
20 Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial Salvatore Siena et al. · The Lancet Oncology 4 May 2021 426
21 Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies Yoshiaki Nakamura et al. · Nature Medicine 5 Oct 2020 380
22 Nationwide Survey on Complementary and Alternative Medicine in Cancer Patients in Japan Ichinosuke Hyodo, Noriko Amano, Kenji Eguchi et al. · Journal of Clinical Oncology Open access 23 Feb 2005 347
23 Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial Chigusa Morizane et al. · Annals of Oncology Open access 26 Sep 2019 338
24 TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki et al. · The Lancet Oncology 27 Aug 2012 326
25 IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Naoyuki Nogami et al. · Journal of Thoracic Oncology Open access 7 Oct 2021 313
26 Differences between right‐ and left‐sided colon cancer in patient characteristics, cancer morphology and histology Toru Nawa, Jun Kato, Hirofumi Kawamoto et al. · Journal of Gastroenterology and Hepatology 27 May 2007 299
27 Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial Kiyotaka Yoh, Takashi Seto, Miyako Satouchi et al. · The Lancet Respiratory Medicine 5 Nov 2016 298
28 Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV ‐8‐negative multicentric Castleman disease Noriko Iwaki et al. · American Journal of Hematology Open access 17 Nov 2015 293
29 A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: The Japan clinical oncology group study Nobutoshi Ando, Toshifumi Iizuka, Teruo Kakegawa et al. · Journal of Thoracic and Cardiovascular Surgery Open access Aug 1997 286
30 Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) K. Yamazaki et al. · Annals of Oncology Open access 14 May 2016 285
31 Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study Ryutaro Kakinuma, Masayuki Noguchi, Kazuto Ashizawa et al. · Journal of Thoracic Oncology Open access 16 Apr 2016 278
32 Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial Ken Kato et al. · The Lancet 12 Jun 2024 276
33 Chemotherapy for hepatocellular carcinoma: current status and future perspectives Masafumi Ikeda, Chigusa Morizane, Makoto Ueno et al. · Japanese Journal of Clinical Oncology Open access 24 Nov 2017 276
34 Focal Ground-Glass Opacity Detected by Low-Dose Helical CT Masao Nakata, Hideyuki Saeki, Ichiro Takata et al. · CHEST Journal May 2002 276
35 A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Kei Muro, Tsuyoshi Hamaguchi, Atsushi Ohtsu et al. · Annals of Oncology Open access 19 May 2004 269
36 Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602 Takashi Onda, Toyomi Satoh, Toshiaki Saito et al. · European Journal of Cancer 18 Jun 2016 259
37 Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study David Scott Miller, Virginia L. Filiaci, Gini F. Fleming et al. · Gynecologic Oncology 17 May 2012 256
38 Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer Open access 4 Dec 2017 247
39 Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome Tsunehisa Kaku, Hiroyuki Yoshikawa, Hitoshi Tsuda et al. · Cancer Letters Jun 2001 246
40 HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy Helena Alexandra Yu et al. · Journal of Clinical Oncology Open access 10 Sep 2023 245
41 Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial Yoshiaki Nakamura et al. · Nature Medicine Open access Nov 2021 245
42 Computer-aided diagnosis for pulmonary nodules based on helical CT images Keizo Kanazawa, Yoshiki Kawata, Noboru Niki et al. · Computerized Medical Imaging and Graphics Mar 1998 241
43 Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system Tomohiro Yamaguchi, Nozomu Machida, Chigusa Morizane et al. · Cancer Science Open access 28 Jun 2014 239
44 Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial Yukihide Kanemitsu et al. · Journal of Clinical Oncology 14 Sep 2021 228
45 Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial Takashi Onda, Toyomi Satoh, Gakuto Ogawa et al. · European Journal of Cancer 13 Mar 2020 227
46 Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · ˜The œLancet. Gastroenterology & hepatology 18 Jan 2017 227
47 Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non–Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR Masaru Watanabe, Tomoya Kawaguchi, Shun‐ichi Isa et al. · Clinical Cancer Research 16 Apr 2015 227
48 Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) Kei Muro, Narikazu Boku, Yasuhiro Shimada et al. · The Lancet Oncology 13 Aug 2010 221
49 Carotenoids in Cancer Chemoprevention Hoyoku Nishino, Michiaki Murakoshi, Tsunehiro Ii et al. · Cancer and Metastasis Reviews Dec 2002 217
50 Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma Keiko Minashi et al. · Gastroenterology Open access 20 Apr 2019 216

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.